S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications

Surabhi Parashar1, David Cheishvili2, Ani Arakelian1, Zahid Hussain1, Imrana Tanvir3, Haseeb Ahmed Khan3, Moshe Szyf2 & Shafaat A. Rabbani1

1Department of Medicine, McGill University Health Centre, Montreal, QC, Canada
2Department of Pharmacology and Therapeutics, McGill University Health Centre, Montreal, QC, Canada
3Fatima Memorial Hospital System, Lahore, Pakistan

Abstract

Osteosarcoma (OS) is an aggressive and highly metastatic form of primary bone cancer affecting young children and adults. Previous studies have shown that hypomethylation of critical genes is driving metastasis. Here, we examine whether hypermethylation treatment can block OS growth and pulmonary metastasis. Human OS cells LM-7 and MG-63 were treated with the ubiquitous methyl donor S-adenosylmethionine (SAM) or its inactive analog S-adenosylhomocysteine (SAH) as control. Treatment with SAM resulted in a dose-dependent inhibition of tumor cell proliferation, invasion, cell migration, and cell cycle characteristics. Inoculation of cells treated with 150 µmol/L SAM for 6 days into tibia or via intravenous route into Fox Chase severe combined immune deficient (SCID) mice resulted in the development of significantly smaller skeletal lesions and a marked reduction in pulmonary metastasis as compared to control groups. Epigenome wide association studies (EWAS) showed differential methylation of several genes involved in OS progression and prominent signaling pathways implicated in bone formation, wound healing, and tumor progression in SAM-treated LM-7 cells. Real-time polymerase chain reaction (qPCR) analysis confirmed that SAM treatment blocked the expression of several prometastatic genes and additional genes identified by EWAS analysis. Immunohistochemical analysis of normal human bone and tissue array from OS patients showed significantly high levels of expression of one of the identified gene platelet-derived growth factor alpha (PDGFA). These studies provide a possible mechanism for the role of DNA demethylation in the development and metastasis of OS to provide a rationale for the use of hypermethylation therapy for OS patients and identify new targets for monitoring OS development and progression.

Introduction

Osteosarcoma (OS) is third most common childhood cancer affecting long bones accounting for 20% of all bone cancers [1, 2]. Late stage OS tumors are known to cause lung metastasis resulting in the high morbidity and mortality. Late stage disease is highly aggressive with 5-year event-free survival in 60–70% patients [3, 4]. While recent advances in neoadjuvant chemotherapy and surgery has improved the long-term survival rates of patients without metastatic disease, patients who exhibit metastasis continue to respond poorly to chemotherapy and have poor prognosis [5–8]. This poor response to therapy is also associated with a high incidence of drug toxicity and efforts to change chemotherapeutic regimen has yielded limited success with no improvement in outcome [9]. Therefore, it is crucial to understand the molecular mechanism of tumor metastasis for early diagnosis, predict prognosis, and identify new targets for the development of more effective therapeutic strategies.

OS is a rare tumor which is often difficult to classify. The primary malignant tumor is characterized by genetic
instability and complex karyotypes [10]. Various mutations, deletions, translocations, and amplifications aid to tumor development [10]. Mostly alterations in two prominent tumor suppressor genes TP53 and RB1 are associated with tumorigenic activity [11]. The p53 and retinoblastoma protein pathways are known for controlling apoptosis, DNA repair, and cell cycle regulation. However, epigenetic mechanisms are also known to contribute to the tumor development process in various types of cancers including OS [12–14]. These epigenetic modifications mainly involve DNA methylation, histone modifications, and chromatin remodeling [15]. The epigenome can regulate the alterations of DNA and associated proteins without affecting the original DNA sequence [16]. One of the fundamental epigenetic modifications is the methylation of cytosine residues in CpG dinucleotides. Atypical methylation patterns have been observed in majority of cancers, which result in the inactivation of tumor suppressor pathways [17]. Additionally, extensive hypomethylation of tumor-promoting genes is also described to enhance the overall process of oncogenesis.

A recent delineation of the landscape of DNA methylation in liver cancer revealed widespread hypomethylation of promoters of genes involved in migration and invasion including several classic prometastatic genes [18]. Hypermethylation of DNA caused by DNA methyltransferase enzymes (DNMTs) and histone acetylation by histone acetyltransferase (HAT) and histone deacetylase (HDAC) has been the prime focus of the epigenetic studies in the recent past [19]. Drugs that target DNMTs and HDAC are under clinical trials for treatment of solid tumors and have already been approved for hematological malignancies [19]. However, inhibition of DNA methylation could also result in activation of prometastatic genes and aggravate cancer metastasis [20, 21]. We therefore proposed that inhibition of demethylation of prometastatic genes could serve as a strategy to block cancer metastasis [22].

SAM is a common cosubstrate involved in methyl group transfer reactions [23]. We have previously shown that SAM treatment causes hypermethylation of urokinase type plasminogen activator (uPA) in breast cancer cells and the knock down of methyl DNA-binding protein 2 resulting in silencing of the uPA gene by reverting the hypomethylated state of this gene in breast and prostate cancer cells [24, 25]. We have also previously shown that SAM could inhibit the proinvasive effects of the DNA methylation inhibitor Vidaza (5-azacytidine) on noninvasive breast cancer cells [25]. We therefore tested in the present study whether methylating agent SAM would be effective in suppressing metastasis in OS in vitro and in vivo using well-established models of OS by effecting key signaling pathways involved in bone remodeling and tumor progression. Since methylation of tumor suppressor genes could stimulate cancer growth, we also determined whether SAM would not exhibit such an adverse effect. Our data show that SAM is effective in inhibiting both invasiveness and tumor growth. These data have important implications on therapy of metastatic OS.

Materials and Methods

Cell culture

Human OS cells LM-7 and MG-63 were obtained from the American Type Culture Collection and maintained in MEM with 10% fetal bovine serum, 2 mmol/L l-glutamine, and 100 units/mL penicillin sulfate/streptomycin sulfate. Cells were incubated with different doses of SAM or SAH (New England Biolabs, Mississauga, ON, Canada) as described previously [25].

Cell proliferation invasion and wounding assay

LM-7 and MG-63 cells were plated in duplicates at a density of 9 × 10^5 and 5 × 10^5 cells, respectively, in 10 mL of culture media in plates. The effect of two different doses of SAM (75.0 and 150.0 μmol/L) was evaluated. The invasive capacity of LM-7 and MG-63 cells was examined using two-compartment Boyden chamber Matrigel invasion assay (Costar Transwell, Corning Corporation, Sigma-Aldrich, Oakville, ON, Canada) following treatment with SAH or SAM for 6 days as described previously [25].

For wound healing analysis, cells LM-7 and MG-63 cells were treated with SAH or SAM (75 and 150 μmol/L) for 6 days in the presence of 10% fetal bovine serum (FBS). Cells were then plated in six-well plates to form a monolayer and then wounded manually with a sterile 1000 μL pipette tip in the center of each well. Cells were grown in the presence of 2% FBS and migrating cells where photographed at different time points. Analysis and quantification was carried out using Image Pro-Plus software and calculated as percentage wound healing using the equation, % wound healing = [1 – (wound area at Tx h/wound area at T0)], where Tx is the respective time point and T0 is the time immediately after wounding. These experiments were repeated twice in duplicates.

Colony formation assay and cell cycle analysis

LM-7 and MG-63 cells at a density of 5000 cells per well previously treated with SAH (150 μmol/L) or SAM (75 and 150 μmol/L) for 6 days were seeded in triplicates into six-well Petri dishes in the presence of 4 mL of culture medium containing 1.5% agar solution at 37°C. Medium
was changed every 48 h. After 14 days post plating, the number of colonies containing more than 100 cells was recorded.

For cell cycle analysis, LM-7 cells were treated with SAH or SAM (75 and 150 μmol/L) every 48 h for 6 days and were fixed by adding 70% of ice-cold ethanol. Fixed cells were washed with phosphate-buffered saline (PBS) and then treated with 1 U of DNase-free RNase and stained with 0.05 mg of propidium iodide for 1 h. Cell cycle analysis was performed on a FACSort Calibur (BD Biosciences, Mississauga, Canada) machine. Results were analyzed further using the FlowJo Software.

**Quantitative real-time polymerase chain reaction**

For quantitative real-time polymerase chain reaction (qPCR) analysis, total cellular RNA from SAH- and SAM-treated LM-7 cells was extracted using TRIZol (Invitrogen Life Technologies, Burlington, ON, Canada) according to the manufacturer’s protocol. Two micrograms of total RNA was used for reverse transcription (RT) reaction. Twenty-five nanograms of cDNA was used in a 20 μL reaction with SYBR green mix, 0.8 μmol/L forward and reverse primers. PCR was performed in an ABI StepOne Plus (Life Technologies, Burlington, Canada) with the following conditions: denaturation at 95°C for 10 min; amplification at 95°C for 15 sec, annealing temperature 1 min, for 40 cycles.

**Illumina Methylation 450K analysis**

LM-7 cells were treated with vehicle or 150 μmol/L of SAM for 6 days. Genomic DNA was quantified using Picogreen protocol (Quant-iT™ PicoGreen® dsDNA Products, Invitrogen, P-7589) and read on a SpectraMAX GeminiXS Spectrophotometer. Bisulfite conversion of 500 ng of genomic DNA was performed using the EZ-96 DNA Methylation-GOLD Kit (Zymo Research, Irvine, CA). The Illumina Methylation 450K kit (San Diego, California, USA) was used for the microarray experiment as described by the manufacturer’s protocol, except that 8 μL of bisulfite converted template was utilized to initiate the amplification step. The Illumina hybridization oven was used for incubating amplified DNA (37°C) and for BeadChips hybridization (48°C). A Hybex incubator was used for fragmentation (37°C) and denaturation (95°C) steps. The X-stain step was carried out in a Tecan Freedom evo robot with a Te-Flow module. Arrays were scanned in Illumina iScan Reader. Data analysis was performed with the Methylation module (version 1.9.0) of the GenomeStudio software (Illumina; version 2011.1) using HumanMethylation450_15017482_v1.2. bmp manifest. Statistical threshold was set at a false discovery rate of >0.05, differential score (statistical power) of >0.13, and delta beta (differential methylation) between the groups was set at >0.15.

**Immunohistochemical analysis of normal bone and clinical biopsies from OS patients**

Tissue microarray slides for OS cases were obtained from US Biomax Inc. (Rockville, MD), whereas all normal cases were from iliac crest. Rabbit polyclonal antibodies for EXOC7 and PCGF3 (Abcam, Toronto, ON, Canada) were used at 1:10, 1:10, and 1:1000 dilution, respectively. Rabbit polyclonal antibody to PDGF AA (Abcam) was used as primary antibody at 1:1000 dilution. Heat-mediated antigen retrieval was performed by Tris/EDTA pH 9.0 buffer, EnvisionTM FLEX Target Retrieval Solution (Dako, Burlington, ON, Canada) at 1:50 dilution; and phosphate buffer containing hydrogen peroxide, 15 mmol/L NaN3 and detergent, EnvisionTM FLEX Peroxidase Blocking Reagent (Dako) was used as blocking reagent. Dextran coupled with peroxidase molecules and goat secondary antibody molecules against rabbit immunoglobulins in buffered solution containing stabilizing protein and preservative, EnvisionTM FLEX/HRP (Dako) was used as secondary antibody for 30 minutes. 3,3'-diaminobenzidine tetrachloride, EnvisionTM FLEX DAB+ Chromogen (Dako) and buffered solution containing hydrogen peroxide and preservative, EnvisionTM FLEX Substrate buffer (Dako) were added. The slides were counterstained with hematoxylin (1a Harris hematoxylin solution by MERCK KGaA, Darmstadt, Germany). Sections were washed twice for 10 min in Tris-buffered saline solution containing Tween 20, pH 7.6 (EnvisionTM FLEX Wash Buffer (Dako) at 1:20 dilution after every step during the procedure. Slides were mounted with DPX (MERCK, KGaA).

Stained slides were scored for proportion and intensity of staining in cells by two pathologists. Staining intensity was assessed as negative, mild, moderate, or strong. Percentage of positive cells showing different intensity staining patterns were noted, and then rounded off to the nearest 10th percentage. Percentage of cells showing mild intensity were given score 1, percentage of cells showing moderate intensity were given score 2, and those with strong intensity staining were given score 3 [26, 27]. A total score was obtained by adding the products of these different intensity scores as follows. Total Score = (percentage of cells with mild intensity staining × 1) + (percentage of cells with moderate intensity staining × 2) + (percentage of cells with strong intensity staining × 3).
**Animal protocols**

For in vivo studies, LM-7 cells were treated with SAH or SAM (150 μmol/L) for 6 days in MEM + 10% FBS. At the end of the treatment, cells were harvested in sterile saline. Six-week-old male Fox Chase severe combined immune deficient (SCID) mice, obtained from Charles River, St-Constant, QC, Canada, were anesthetized using a cocktail of ketamine (50 mg/kg), xylazine (5 mg/kg), and acepromazine (1 mg/kg) intramuscularly. LM-7 cells viability was confirmed by Trypan blue assay and cells were inoculated at 2 × 10^5 cells per mouse in 40 μL saline with a 27-gauge needle into the left tibia using a drilling motion. The mice were monitored weekly for tumor burden. On week 4, a digital radiography of hind limbs of all animals was done using a Faxitron X-ray machine (Faxitron X-ray Corp., Lincolnshire, IL) to monitor the development of skeletal lesions. The mice were then euthanized, and the left tibias were collected and fixed in 10% buffered formalin solution for 24 h. The X-ray scoring method is described as follows: no lesions or minor changes, small lesions, significant lesions (minor peripheral margin breaks, 1–10% of bone surface disrupted), and significant lesions (major peripheral margin breaks, >10% of bone surface broken) rating 0–4, respectively [28–32].

In lung metastasis studies, LM-7 cells treated with 150 μmol/L of SAH or SAM were inoculated in 6-week-old female BALB/c nude mice, tumor formation and pulmonary metastasis was monitored for a period of 14 weeks [33, 34]. Control and experimental animals were sacrificed at the end of this period and lungs were harvested and fixed. Metastatic nodules were counted on surfaces of all lung lobes and the number recorded as the number of lung metastases for each tumor-bearing animal. All the experimental animal protocols were in accordance with the McGill University Animal Care Committee guidelines.

**Statistical analysis**

Results were analyzed as the mean ± SEM, and comparisons of the experimental data were analyzed by an independent two-sample t-test at P < 0.05 level of significance.

**Results**

**Effect of SAM on OS cells proliferation, invasion, and migration**

Methylation of tumor suppressor genes could result in increased growth rate, which might counteract any antimetastatic property of SAM. We therefore first determined whether SAM treatment would result in adverse increase in cancer cell growth rate. We examined the effect of SAH and SAM treatment on two invasive human OS cell lines LM-7 and MG-63. Treatment of LM-7 and MG-63 with 75 and 150 μmol/L dose of SAM for 6 days resulted in significant inhibition of LM-7 and MG-63 cell proliferation as compared to control cells treated with similar doses of SAH (Fig. 1A).

We then determined whether SAM treatment affects the invasive potential of OS cells using Boyden chamber Matrigel invasion assay. Treatment of LM-7 and MG-63 cell lines with different doses (75 and 150 μmol/L) of SAM reduced tumor cells invasion in a dose-dependent manner (Fig. 1B). In order to rule out the possible confounding antiproliferative effects of SAM as shown in panel A, we counted the tumor cells in both upper and lower part of Boyden chamber. Results from this analysis showed similar number of tumor cells during this treatment demonstrating that the observed anti-invasive effects are not due to the ability of SAM to alter cell proliferation.

The effect of SAM on cell migration was analyzed by wound healing assay using LM-7 and MG-63 cell lines. A significant reduction in wound healing (%) was observed in SAM-treated (75 and 150 μmol/L) LM-7 cells compared with SAH-treated control cells at 48, 72, and 120 h and MG-63 cells at 24, 48, and 72 h after wounding (Fig. 2). At 120 and 72 h, 150 μmol/L of SAM was most effective in blocking cell migration in LM-7 and MG-63, respectively.

**Effect of SAM on colony formation and cell cycle**

Tumor cell’s ability to form colonies in soft agar is an index of their aggressive potential. We therefore examined the effect of SAM on the number of colonies formed by LM-7 and MG-63 cells. Following treatment of these cells with (75 and 150 μmol/L) of SAM, a significant and dose-dependent decrease in the number of colonies formed was observed compared to control (SAH-treated) group of cells (Fig. 3A).

We then examined the effects of different doses (75 and 150 μmol/L) of SAM on cell cycle kinetics to further confirm that SAM treatment would not result in silencing of tumor suppressor mechanisms and enhancement of cell cycle progression. FACS analysis of cell cycle distribution on control and SAM-treated cells showed a significant increase in the number of tumor cells in G2/M phase with simultaneous decrease in S phase in the SAM treatment group as compared to control group of cells (Fig. 3B). Thus, not only does SAM accelerate the progression of the cell cycle as anticipated if it silenced tumor suppressor genes but also it inhibits progression through arresting cells at the G2/M phase of the cell cycle.
Next, we examined the effect of SAM on development and progression of skeletal lesions in our xenograft model of OS by using highly invasive LM-7 cells. Control and SAM (150 μmol/L)-treated LM-7 cells were inoculated directly into the tibia of male Fox Chase mice as described in “Materials and Methods” section. Control animals developed skeletal lesions at week 8 which continued to increase in size and number of lesions over time. In contrast, animals treated with LM-7 cells treated with SAM exhibited reduced total skeletal lesion area (~34%) represented as X-ray score as compared to the control group of animals inoculated with SAH at week 8 post tumor cell inoculation (Fig. 4A).

Since lung metastasis is a common occurrence in OS, we next examined the effect of SAM treatment on the development of lung metastasis using our lung metastasis model as described in “Materials and Methods” section. Control animals inoculated with SAH-treated LM-7 cells developed large lung metastasis detected at the end of these studies 14 weeks post tumor cell inoculation. In contrast, experimental animals inoculated with SAM-treated LM-7 cells exhibited a marked decrease in number and size of lung metastasis (Fig. 4B).

**Effects of SAM on epigenome wide methylation in OS**

SAM is a global hypermethylating agent raising the concern that it will indiscriminately affect DNA methylation particularly methylating tumor suppressor genes, which could result in enhancing cancer cell growth. Although our cellular studies described in Figures 1 and 3...
demonstrated that SAM did not block tumor suppressor mechanisms, but rather enhanced tumor suppression. It is nevertheless important to exclude the possibility that SAM increases methylation of tumor suppressor genes. We therefore performed an epigenome-wide analysis of the changes in DNA methylation triggered by SAM using Illumina 450K bead arrays which provide a representative coverage of CGs at transcription start sites, 5' regulatory regions, CG shores as well as in the gene bodies. DNA was isolated from LM-7 cells treated with 150 μmol/L S-adenosylhomocysteine as control (SAH) or two different doses of SAM (75 and 150 μmol/L) containing 2% fetal bovine serum and migrating cells were photographed at different time points. Percent wound healing was recorded at different time points, and percentage of wound healing with respect to T₀ was calculated using the equation described in "Materials and Methods" section. Results are presented as the mean ± SEM of two different experiments in duplicate from control and experimental cells. Significant differences from the control (SAH) is represented by an asterisk (*P < 0.05).

**Effect of SAM on the expression of OS-associated genes**

Due to the complex nature of OS progression several molecular pathways and genes are implicated in its limited effect on the methylome. None of the known tumor suppressor genes altered their state of methylation in response to SAM treatment, while the sites that were hypermethylated were associated with genes that were known to play a key role in tumor growth and metastasis (Table S1). Ingenuity pathway analysis (IPA) showed that the hypermethylated genes are members of key intracellular signaling pathways that are known to be involved in OS growth and metastasis, but there were no genes in tumor suppressor pathways that seem to be affected (Table S2).
growth and metastasis. In order to understand the antitumor effects of SAM, we first analyzed the expression of well-established genes which are known to alter tumor cell proliferation, invasion, and metastasis as well as genes that were hypermethylated by 150 \( \mu \text{mol/L} \) 6 d SAM treatment as determined by the Illumina bead array analyses (Tables S1, S2). The qPCR results presented in Figure 6 show the analysis of RNA from control and 150 \( \mu \text{mol/L} \) SAM-treated cells. SAM treatment reduced the expression of genes implicated in tumor cell invasion, metastasis, and angiogenesis such as matrix metalloproteinase (MMP) 2 and 9, vascular endothelial growth factor (VEGF), plasminogen activator inhibitor 1 (PAI-1), and uPA. Additionally, SAM treatment also markedly reduced the expression of transforming growth factor \( \beta \) (TGF-\( \beta \)) and runt-related transcription factor 2 (RUNX2) (Fig. 5A).

We also selected three representative genes of Exocyst Complex Component 7 (EXOC7), Polycomb Group Ring Finger 3 (PCGF3), and Platelet-Derived Growth Factor Alpha (PDGFA) which were found to be hypermethylated following SAM treatment. These genes are involved with several intracellular signaling pathways that are known to affect tumor growth and metastasis [35–38]. qPCR analysis of control and experimental LM-7 cells show that
expression of these genes was markedly reduced following SAM treatment supporting the hypothesis that SAM triggered hypermethylation leads to silencing of several genes critical for metastasis (Fig. 5B).

**Expression of new candidate genes in cancer and normal tissues**

We determined the levels of expression of these genes (EXOC7, PCGF3, PDGFA) in normal bone and clinical biopsies from OS patients in a tissue array using commercially available antibodies as described in “Material and Methods” section. Results from OS array demonstrated a higher PDGFA expression in different stages of OS as compared to normal bone \((P < 0.05)\). No significant differences in the level of expression of PDGFA were observed between different stages of OS (Fig. 6). Antibodies against EXOC7 and PCGF3 showed a high nonspecific staining at multiple dilutions resulting in inconclusive results for immunohistochemistry (data not shown).

**Discussion**

Aberrations in DNA methylation pattern is one of the hallmarks of cancer where by controlling the transcription of tumor suppressor and prometastatic genes it can regulate the multistep process of tumor progression [39]. In the majority of studies, to date focus has been on understanding the hypermethylation of tumor suppressor genes and targeting these processes therapeutically, whereas little attention was paid to the potential role of hypomethylation of prometastatic genes. However, an increasing body of evidence suggests that hypomethylation of prometastatic genes could promote cancer metastasis. This points to the possibility that drugs that induce hypermethylation of prometastatic genes could serve as antimetastatic agents. We have previously shown that the ubiquitous methyl donor SAM can inhibit DNA demethylation in vitro and in vivo [24, 25] and can lead to hypermethylation and silencing of prometastatic genes. SAM is a particularly attractive agent since it is a
DNA Methylation Inhibit Tumor Metastasis

S. Parashar et al.

Figure 5. Effect of S-adenosylmethionine (SAM) on the expression of genes associated with osteosarcoma (OS) metastasis. LM-7 cells were treated with 150 μmol/L of S-adenosylhomocysteine as control (SAH) or with 150 μmol/L of SAM for 7 days, and total cellular RNA was isolated with TRIzol. RNA from control and treatment groups were analyzed for the expression of genes involved in tumor progression and skeletal metastasis (A) and hypomethylated genes identified by Illumina analysis (B). Changes in the mRNA expression of the representative genes were determined by plotting the relative ratio against GAPDH which was used as loading control. Results are presented as the mean ± SEM of two different experiments in duplicate from control and experimental cells. Significant differences from the control (SAH) is represented by an asterisk (P < 0.05).

FDA-approved nutritional supplement with little documented toxicity.

In this study, we provide a proof of principle that SAM could act as an antimetastatic agent in OS. Toward these goals, we used two in vivo models of OS which allowed the evaluation of the effect of SAM in bone and in blocking distant metastasis (lungs). Combined with these models, we used several in vitro assays to determine the mechanism of these antitumor effects of SAM. The first concern with using a hypermethylating agent in cancer is that it will lead to silencing of tumor suppressor genes through increased DNA methylation and that such an effect will override its beneficial effects on inhibition of metastasis. Our results show that SAM treatment had a significant effect on reducing tumor cell proliferation and altering cell cycle kinetics by reducing the number of cells in S phase and arresting them at G2/M phase. This suggests that SAM does not inhibit tumor suppressor mechanisms; on the contrary, SAM triggers mechanisms that arrest cell growth and makes them susceptible to radio- and chemotherapy. As hypothesized, SAM inhibited invasion and migration and thus blocked basic mechanisms driving metastasis while avoiding silencing of tumor suppressor mechanisms. Although SAM reduced both proliferation and invasion, the effects of SAM on cell invasion were found to be independent of cell death or inhibition of proliferation as similar number of control (SAH) and experimental (SAM) treated LM-7 cells were observed in upper parts of Boyden (Fig. 1). We then evaluated the effect of SAM on OS metastasis in vivo. Inoculation of SAM-treated cells exhibited a significantly reduced number of lung metastasis when injected via tail vein in vivo. In vivo SAM treatment did not increase cell proliferation as anticipated if tumor suppressor genes were silenced by this hypermethylating agent but resulted in inhibition of cell proliferation. The fact that transient treatment in vitro was sufficient to block invasion and growth in vivo without further treatment with SAM is consistent with the hypothesis that the “in vitro” treatment epigenetically “reprogrammed” the OS cells to become less invasive and tumorigenic. The ability of epigenetic drugs to “reprogram” cancer cells carries important therapeutic advantage. The specificity of these SAM-mediated effects was confirmed by simultaneous treatment with its inactive analog SAH which lacks the methyl group and does not cause hypermethylation and showed no effects on invasion and growth.

Although SAM is a global hypermethylating agent, the biological effects observed suggest specificity [40]. A plausible mechanism for SAM action is that it results in coordinate silencing of critical genes for OS metastasis but does not silence tumor suppressor genes. In order to understand the underlying molecular mechanism mediating these significant in vitro and in vivo effects, we first examined the change in the levels of expression of genes implicated in tumor metastasis in general and skeletal metastasis in particular. PCR analysis of control (SAH) and experimental (SAM) treated LM-7 cells showed a marked inhibition in the expression of tumor-promoting genes (MMP-2, MMP-9, VEGF, PAI-1, and uPA) and genes (uPA, TFG-β, and RUNX2) which are known to promote the development and progression of skeletal metastasis. MMP-2 and MMP-9 are two key regulators of extracellular matrix (ECM) remodeling and play a crucial role in angiogenesis, migration of cancer cells and metastasis. VEGF is a major angiogenic growth factor [41].
uPA and PAI-1 are integral components of plasminogen activator system and play important roles in ECM degradation and invasion of cancer cells [42, 43]. TGF-β and RUNX2 are involved in osteoblast differentiation and skeletal metastasis [43, 44]. TGF-β arrests cell cycle at G1 phase and initiates differentiation or apoptosis of normal cells; however, in metastatic cancer it is known to stimulate invasion and metastasis by up-regulating the uPA mRNA and SMAD4 signaling [9, 45]. RUNX2 is a gene which has a well-established role in bone biology and skeletal metastasis [46]. Recently, it has been shown that increased residence of RUNX2 at mitotic chromosomes may reflect its epigenetic function in “bookmarking” of target genes in cancer cells [47]. The fact that SAM targeted these genes provides a plausible mechanism for its anti-OS effects seen in our study.

The idea that SAM has a specific effect on OS that targets prometastatic genes for silencing but not tumor suppressor genes was supported by a methylome analysis of changes in DNA methylation in LM-7 triggered by SAM (Table S1). Remarkable in spite of the fact that it is a general methyl donor only a small number of genes were affected by SAM (Table S1), but they seem to particularly target critical pathways for metastasis and tumor growth (Table S2). Ingenuity pathway analysis of these genes that became differentially methylated are involved in critical signaling pathways that were known to play a role in tumorigenesis but none of the known tumor suppressor genes that are hypermethylated in cancer. Following IPA analysis, we selected three genes that are hypermethylated by SAM treatment (EXOC7, PCGF3, PDGFA) which are implicated in several key intracellular signaling pathways, regulation of gene transcription, and tumorogenesis as shown in Table S1. We then determined the change in the levels of expression of these candidate genes (EXOC7, PCGF3, and PDGFA) in OS cells following treatment with SAM. Experimental cells treated with SAM showed a marked suppression in the expression of these genes as determined by qPCR analysis.

Using immunohistochemical analysis, we determined the significance of identified genes (EXOC7, PCGF3, PDGFA) in the OS development and progression. Toward these goals we used commercially available OS tissue array and normal bone from our institution. Commercially available antibodies against EXOC7 and PCGF3 showed high nonspecific staining at multiple dilutions and results from these studies are not shown. However, antibody against PDGFA showed specific staining of bone cells.

Figure 6. Immunohistochemical analysis for platelet-derived growth factor alpha (PDGFA) expression in normal bone and osteosarcoma patients. Tissue array obtained from osteosarcoma patients of different stages (IA, IB, IIA, IIB) as defined by the American Cancer Society and normal bone (Normal) were stained with PDGFA-specific antibody and staining intensity was quantitated as described in “Materials and Methods” section. The staining intensity was calculated and a total mean staining score = (Percentage of cells with mild intensity staining × 1) + (Percentage of cells with moderate intensity staining × 2) + (Percentage of cells with strong intensity staining × 3) was calculated and represented in (lower panel). Representative images from normal bone and different stages of osteosarcoma are shown (upper panel). Significant differences from control are represented by asterisks (P < 0.05).
Results of this analysis as shown in Figure 6 show low levels of PDGFA expression normal bone samples. In contrast, PDGFA expression was markedly high in OS patients. While these results clearly showed the induction of PDGFA in OS, limited number of samples from early stages (Ia, Ib) restricted our ability to establish a correlation with disease progression. These results are particularly significant as PDGFA is upregulated in several cancers due to its ability to alter cell proliferation, differentiation, angiogenesis, and metastasis [38, 48, 49].

Collectively, these results provide support that SAM can serve as a viable and attractive anticancer agent which blocks various tumor-promoting genes and signaling pathways. Our studies identify OS “signature” candidate genes, which are hypomethylated in OS and may serve as efficient biomarkers for diagnosis and prognosis of OS patients. Since SAM is already being used in oral formulation, it can provide beneficial effects in both preventive and therapeutic settings using improved and stable forms of SAM. Results from these studies also provide new therapeutic opportunities where methylation therapy alone or in combination with various therapeutic strategies currently under development to target genes which we have identified like uPA and its receptor to elicit strong synergistic effects to significantly reduce morbidity and mortality in cancer patients in general and those with OS in particular.

Acknowledgments

This work was supported by a grant MOP 130410 from the Canadian Institutes for Health Research to S. A. Rabani and M. Szyf. D. Cheishvili is funded by a postdoctoral fellowship from the Israel Cancer Research Fund (ICRF).

Conflict of Interest

None declared.

References

1. Rainusso, N., L. L. Wang, and J. T. Yustein. 2013. The adolescent and young adult with cancer: state of the art—bone tumors. Curr. Oncol. Rep. 15:296–307.
2. Ottaviani, G., and N. Jaffe. 2009. The epidemiology of osteosarcoma. Cancer Treat. Res. 152:3–13.
3. Meyers, P. A., G. Heller, J. Healey, A. Huvos, J. Lane, R. Marcove, et al. 1992. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J. Clin. Oncol. 10:5–15.
4. Ferrari, S., A. Briccoli, M. Mercuri, F. Bertoni, M. Cesari, A. Longhi, et al. 2006. Late relapse in osteosarcoma. J. Pediatr. Hematol. Oncol. 28:418–422.
5. Bielack, S. S., B. Kempf-Bielack, G. Delling, G. U. Exner, S. Flege, K. Helmke, et al. 2002. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 20:776–790.
6. Wang, L. L. 2005. Biology of osteogenic sarcoma. Cancer J. 11:294–305.
7. Ferguson, W. S., and A. M. Goorin. 2001. Current treatment of osteosarcoma. Cancer Invest. 19:292–315.
8. Marina, N., M. Gebhardt, L. Teot, and R. Gorlick. 2004. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422–441.
9. Munoz Villa, A., G. Ocete, M. L. Aymerich, S. Maldonado, E. Otheo, M. Calvo, et al. 1996. Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children. Med. Clin. (Barc.) 107:161–164.
10. Szuhaï, K., A.-M. Cleton-Jansen, P. C. W. Hogendoorn, and J. V. M. G. Bovee. 2012. Molecular pathology and its diagnostic use in bone tumors. Cancer Genet. 205:193–204.
11. Rao-Bindal, K., and E. S. Kleinerman. 2011. Epigenetic regulation of apoptosis and cell cycle in osteosarcoma. Sarcoma 2011:679457.
12. Esteller, M. 2007. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8:286–298.
13. Das, P. M., K. Ramachandran, J. Vanwert, L. Ferdinand, G. Gopisetty, I. M. Reis, et al. 2006. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol. Cancer. 5:28.
14. Al-Romaih, K., B. Sadikovic, M. Yoshimoto, Y. Wang, M. Zielenska, and J. A. Squire. 2008. Decitabine-induced demethylation of 5’ CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia 10:471–480.
15. Cote, G. M., and E. Choy. 2013. Role of epigenetic modulation for the treatment of sarcoma. Curr. Treat. Options Oncol. 14:454–464.
16. Horsthemke, B. 2006. Epimutations in human disease. Curr. Top. Microbiol. Immunol. 310:45–59.
17. Lee, C. J., J. Evans, K. Kim, H. Chae, and S. Kim. 2014. Determining the effect of DNA methylation on gene expression in cancer cells. Methods Mol. Biol. 1101:161–178.
18. Stefanska, B., J. Huang, B. Bhattacharyya, M. Suderman, M. Hallett, Z. G. Han, et al. 2011. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 71:5891–5903.
19. Connolly, R., and V. Stearns. 2012. Epigenetics as a therapeutic target in breast cancer. J. Mammary Gland Biol. Neoplasia 17:191–204.
20. Chik, F., and M. Szyf. 2011. Effects of specific DNM1 gene deletion on cancer cell transformation and breast cancer.
cell invasion; toward selective DNMT inhibitors. Carcinogenesis 32:224–232.
21. Ateeq, B., A. Unterberger, M. Szyf, and S. A. Rabbani. 2008. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10:266–278.
22. Szyf, M., P. Pakneshan, and S. A. Rabbani. 2004. DNA demethylation and cancer: therapeutic implications. Cancer Lett. 211:133–143.
23. Boal, A. K., T. L. Grove, M. I. McLaughlin, N. H. Yennawar, S. J. Booker, and A. C. Rosenzweig. 2011. Structural basis for methyl transfer by a radical SAM enzyme. Science 332:1089–1092.
24. Pakneshan, P., M. Szyf, R. Farias-Eisner, and S. A. Rabbani. 2004. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J. Biol. Chem. 279:31735–31744.
25. Shukeir, N., P. Pakneshan, G. Chen, M. Szyf, and S. A. Rabbani. 2006. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66:9202–9210.
26. Kinsel, L. B., E. Szabo, G. L. Greene, J. Konrath, G. S. Leight, and K. S. McCarty, Jr.. 1989. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 49:1052–1056.
27. Mazières, J., W. Brugger, F. Cappuzzo, P. Middel, A. Frosch, I. Bara, et al. 2013. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 82:231–237.
28. Rabbani, S. A., A. Arakelian, and R. Farookhi. 2013. LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2:625–635.
29. Rabbani, S. A., B. Ateeq, A. Arakelian, M. L. Valentino, D. E. Shaw, L. M. Dauffenbach, et al. 2010. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 12:778–788.
30. Rabbani, S. A., M. L. Valentino, A. Arakelian, S. Ali, and F. Boschelli. 2010. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol. Cancer Ther. 9:1147–1157.
31. Khalili, P., A. Arakelian, G. Chen, M. L. Plunkett, I. Beck, G. C. Parry, et al. 2006. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 5:2271–2280.
32. Khalili, P., A. Arakelian, G. Chen, G. Singh, and S. A. Rabbani. 2005. Effect of Hereceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene 24:6657–6666.
33. Graat, H. C., V. W. van Beusechem, F. H. Schagen, M. A. Witlox, E. S. Kleinerman, M. N. Heldr, et al. 2008. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol. Cancer. 7:9.
34. Rastelli, L., M. L. Valentino, M. C. Minderman, J. Landin, U. M. Malyankar, M. K. Lescoe, et al. 2011. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo. Int. J. Oncol. 39:401–408.
35. Yau, C., L. Esserman, D. H. Moore, F. Waldman, J. Sninsky, and C. C. Benz. 2010. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 12:R85.
36. Valk-Lingbeek, M. E., S. W. Bruggeman, and M. van Lohuizen. 2004. Stem cells and cancer; the polycmb connection. Cell 118:409–418.
37. Gil, J., D. Bernard, and G. Peters. 2005. Role of polycmb group proteins in stem cell self-renewal and cancer. DNA Cell Biol. 24:117–125.
38. Tripurani, S. K., R. W. Cook, K. W. Eldin, and S. A. Pangas. 2013. BMP-specific SMADs function as novel repressors of PDGFA and modulate its expression in ovarian granulosa cells and tumors. Oncogene 32:3877–3885.
39. Baylin, S. B., M. Esteller, M. R. Rountree, K. E. Bachman, K. Schuebel, and J. G. Herman. 2001. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10:687–692.
40. Detich, N., S. Hamm, G. Just, J. D. Knox, and M. Szyf. 2003. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J. Biol. Chem. 278:20812–20820.
41. Goel, H. L., and A. M. Mercurio. 2013. VEGF targets the tumour cell. Nat. Rev. Cancer 13:871–882.
42. Kwaan, H. C., A. P. Mazar, and B. J. McMahon. 2013. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin. Thromb. Hemost. 39:381–391.
43. Wakefield, L. M., and C. S. Hill. 2013. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat. Rev. Cancer 13:328–341.
44. Chimge, N. O., and B. Frenkel. 2013. The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 32:2121–2130.
regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta. J. Biol. Chem. 281:33971–33981.

46. Akech, J., J. J. Wixted, K. Bedard, M. van der Deen, S. Hussain, T. A. Guise, et al. 2010. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811–821.

47. Pockwinse, S. M., K. P. Kota, A. J. Quaresma, A. N. Imbalzano, J. B. Lian, A. J. van Wijnen, et al. 2011. Live cell imaging of the cancer-related transcription factor RUNX2 during mitotic progression. J. Cell. Physiol. 226:1383–1389.

48. Boonjaraspinyo, S., Z. Wu, T. Boonmars, S. Kaewkes, W. Loilome, P. Sithithaworn, et al. 2012. Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol. Int. 61:145–150.

49. Martinho, O., A. Longatto-Filho, M. B. Lambros, A. Martins, C. Pinheiro, A. Silva, et al. 2009. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFR) and its ligand PDGFA in gliomas. Br. J. Cancer 101:973–982.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Differentially methylated genes and their functions.

Table S2. Ingenuity pathway analysis of hypermethylated genes in SAM-treated LM-7 cells.